Nightstar Therapeutics (NASDAQ:NITE) had its target price increased by Leerink Swann from $30.00 to $35.00 in a research report released on Monday morning, The Fly reports. The brokerage currently has a positive rating on the stock.
Several other research analysts have also weighed in on the company. Mizuho upped their target price on Nightstar Therapeutics to $24.00 and gave the stock a buy rating in a research report on Tuesday, September 4th. Janney Montgomery Scott assumed coverage on Nightstar Therapeutics in a research report on Wednesday, August 22nd. They issued a buy rating and a $34.00 target price on the stock. Zacks Investment Research raised Nightstar Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 9th. UBS Group lowered Nightstar Therapeutics from an outperform rating to a market perform rating in a research report on Wednesday, June 27th. Finally, Chardan Capital reaffirmed a buy rating and issued a $40.00 target price on shares of Nightstar Therapeutics in a research report on Wednesday, June 6th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $32.86.
Shares of Nightstar Therapeutics stock opened at $19.00 on Monday. Nightstar Therapeutics has a 1 year low of $10.01 and a 1 year high of $29.55.
A number of hedge funds have recently modified their holdings of the business. Partner Fund Management L.P. increased its position in Nightstar Therapeutics by 0.7% in the 2nd quarter. Partner Fund Management L.P. now owns 1,016,980 shares of the company’s stock worth $16,272,000 after purchasing an additional 7,007 shares during the last quarter. Bank of America Corp DE acquired a new position in Nightstar Therapeutics in the 2nd quarter worth about $132,000. Stanley Laman Group Ltd. acquired a new position in Nightstar Therapeutics in the 2nd quarter worth about $195,000. Redmile Group LLC increased its position in Nightstar Therapeutics by 0.9% in the 2nd quarter. Redmile Group LLC now owns 1,785,446 shares of the company’s stock worth $28,567,000 after purchasing an additional 16,500 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Nightstar Therapeutics in the 1st quarter worth about $507,000. 28.62% of the stock is currently owned by institutional investors.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy.
Recommended Story: Fundamental Analysis and Individual Investors
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.